THE INSTITUTE FOR ETHNOMEDICINE INC
Programs
Program 1 [2020]
Research by the Institute and members of our global scientific consortium identified the amino acid L-serine as a potential drug candidate. The Institute has studied the potential of L-serine as a novel therapy for the treatment of ALS and other neurodegenerative illnesses through in vitro and in vivo experiments, as well as FDA-approved human clinical trials. These experiments suggest that while L-serine at the doses studied cannot stop or reverse neurodegeneration associated with ALS, that L-serine may slow disease progression.GeographiesNot indicatedDatesJan 1, 2020 – Dec 31, 2020Source990No causes providedNo populations provided–$2.3MBrain Disease Research Initiative
The Brain Chemistry Labs seeks to discover novel ways of preventing, diagnosing, and treating brain diseases. Our current focus is on progressive neurodegenerative diseases characterized by protein misfolds, including Alzheimers, ALS, Parkinsons, and Lewy Body disease. We are sponsoring a randomized, double-blinded, placebo-controlled Phase II clinical trial of the amino acid L-serine for the treatment of Mild Cognitive Impairment (a precursor of Alzheimers disease) at Houston Methodist Research Institute. We are currently raising funds for advanced clinical trials of L-serine for ALS, and a clinical trial for WY40687, a new drug we have discovered for advanced Parkinsons disease. We have discovered microRNA fingerprints, extracted from extracellular vesicles in the bloodstream, which are diagnostic for ALS as well as a novel metabolite which is diagnostic for early-stage Alzheimers disease. We have also discovered that naturally occurring small proteins, called cyclotides, may be useful as chemotherapy adjuvants for glioblastoma.GeographiesNot indicatedDatesJan 1, 2023 – Dec 31, 2023Source990No causes providedNo populations provided–$2.3M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)